Dr. Nathan Fowler is Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas. He received his MD and completed his residence at the University of Texas. Dr. Fowler then went on to complete a clinical fellowship in hematology/oncology at Georgetown University where he was a chief fellow.
Dr. Fowler’s interest in immunomodulatory agents began during his hematology/oncology fellowship at George University Hospital, where he helped develop some of the first protocols to use lenalidomide in CLL. His focus at MD Anderson has been the further development of novel therapeutic regimens with immunomodulatory therapies to help patients with low-grade non-Hodgkin lymphoma. Dr. Fowler also serves as the chairman of several Phase I and investigator-initiated Phase II trials for patients with non-Hodgkin lymphoma.